Top

Published in:

01-06-2007 | Original Paper

Interferon-α2a and Vogt–Koyanagi–Harada disease: a double-edged sword?

Authors: Valerie Touitou, Damien Sene, Christine Fardeau, Thi-Huong-Du Boutin, Pierre Duhaut, Jean-Charles Piette, Phuc LeHoang, Patrice Cacoub, Bahram Bodaghi

Published in: International Ophthalmology | Issue 2-3/2007

Abstract

Successful therapy based on the use of interferon-α has been reported in different types of severe chronic uveitis. The immunomodulatory effects of this drug, combined with its antiviral properties seem to contribute to its efficacy in the treatment of different forms of severe and refractory uveitis such as Vogt-Koyanagi-Harada disease, Behçet-associated uveitis, or even human herpes virus 8 (HHV-8) associated uveitis. At the same time, severe ocular complications have been reported in patients treated with interferon-α for chronic viral hepatitis C. Among these complications, six cases of Vogt–Koyanagi–Harada-like disease have been described.

We report a small case series of two patients with refractory Vogt–Koyanagi–Harada disease, treated with interferon-α and discuss the potential benefits or detrimental role of interferon therapy in these patients.

Wechsler B, Bodaghi B, Huong DL et al (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet’s disease. Ocul Immunol Inflamm 8:293–301PubMedCrossRef

Pivetti-Pezzi P, Accorinti M, Pirraglia MP et al (1997) Interferon alpha for ocular Behcet’s disease. Acta Ophthalmol Scand 75:720–722PubMedCrossRef

Okada AA (2000) Drug therapy in Behcet’s disease. Ocul Immunol Inflamm 8:85–91 (in press)PubMedCrossRef

Bodaghi B, Gendron G, Wechsler B et al (2006) Efficacy of interferon alpha in the treatment of refractory and sight-threatening uveitis : a retrospective monocentric study of 45 patients. Br J Ophthalmol (in press)

Deuter CM, Koetter I, Guenaydin I et al (2006) Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 26:786–791PubMedCrossRef

Brasnu E, Wechsler B, Bron A et al (2005) Efficacy of interferon-alpha for the treatment of Kaposi’s sarcoma herpesvirus-associated uveitis. Am J Ophthalmol 140:746–748PubMedCrossRef

Matsuo T, Takabatake R (2002) Multiple sclerosis-like disease secondary to alpha interferon. Ocul Immunol Inflamm 10:299–304PubMedCrossRef

Perlemuter G, Bodaghi B, Le Hoang P et al (2002) Visual loss during interferon-alpha therapy in hepatitis C virus infection. J Hepatol 37:701–702PubMedCrossRef

Yamada H, Mizobuchi K, Isogai Y (1994) Acute onset of ocular complications with interferon. Lancet 343:914PubMedCrossRef

10.

Sylvestre DL, Disston AR, Bui DP (2003) Vogt–Koyanagi–Harada disease associated with interferon alpha-2b/ribavirin combination therapy. J Viral Hepat 10:467–470PubMedCrossRef

11.

Touitou V, Bodaghi B, Cassoux N et al (2005) Vogt–Koyanagi–Harada disease in patients with chronic hepatitis C. Am J Ophthalmol 140:949–952PubMedCrossRef

12.

Kasahara A, Hiraide A, Tomita N et al (2004) Vogt–Koyanagi–Harada disease occurring during interferon alpha therapy for chronic hepatitis C. J Gastroenterol 39:1106–1109PubMedCrossRef

13.

Arnaud P (2002) [The interferons: pharmacology, mechanism of action, tolerance and side effects]. Rev Med Interne 23(Suppl 4):449s–458sPubMedCrossRef

14.

Sanda C, Weitzel P, Tsukahara T et al (2006) Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res 26:462–472PubMedCrossRef

15.

Okada AA, Keino H, Suzuki J et al (1998) Kinetics of intraocular cytokines in the suppression of experimental autoimmune uveoretinitis by type I IFN. Int Immunol 10:1917–1922PubMedCrossRef

16.

Okada AA, Keino H, Fukai T et al (1998) Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 6:215–226PubMedCrossRef

17.

Stubiger N, Crane IJ, Kotter I et al (2003) Interferon alpha 2a in IRPB-derived peptide-induced EAU–part I. Adv Exp Med Biol 528:537–540PubMed

18.

Treusch M, Stubiger N, Vonthein R et al (2003) Influence of interferon-alpha on lymphocyte subpopulations in Behcet’s disease. Adv Exp Med Biol 528:533–535PubMedCrossRef

19.

Treusch M, Vonthein R, Baur M et al (2004) Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet’s disease. Rheumatology (Oxford) 43:1275–1282CrossRef

20.

Kotter I, Gunaydin I, Treusch M et al (2003) The use of interferon-alpha in Behcet’s disease–review of the literature and possible mechanisms of action. Adv Exp Med Biol 528:503–509PubMed

21.

Pellicano R, Smedile A, Peyre S et al (2005) Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist’s view. Minerva Gastroenterol Dietol 51:55–61PubMed

22.

Selmi C, Lleo A, Zuin M et al (2006) Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 7:451–456PubMed

23.

Oshima Y, Harino S, Hara Y et al (1996) Indocyanine green angiographic findings in Vogt–Koyanagi–Harada disease. Am J Ophthalmol 122:58–66PubMed

24.

Harada T, Kanbara Y, Takeuchi T et al (1997) Exploration of Vogt–Koyanagi–Harada syndrome by infrared choroidal angiography with indocyanine green. Eur J Ophthalmol 7:163–170PubMed

25.

Bouchenaki N, Herbort CP (2001) The contribution of indocyanine green angiography to the appraisal and management of Vogt–Koyanagi–Harada disease. Ophthalmology 108:54–64PubMedCrossRef

26.

Gupta R, Singh S, Tang R et al (2002) Anterior ischemic optic neuropathy caused by interferon alpha therapy. Am J Med 112:683–684PubMedCrossRef

27.

Vardizer Y, Linhart Y, Loewenstein A et al (2003) Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy. J Neuroophthalmol 23:256–259PubMed

28.

Norcia F, Di Maria A, Prandini F et al (1999) Natural interferon therapy: optic nerve ischemic damage? Ophthalmologica 213:339–340PubMedCrossRef

29.

Purvin VA (1995) Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 113:1041–1044PubMed

30.

van der Eijk AA, Vrolijk JM, Haagmans BL (2006) Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. N Engl J Med 354:1323–1324PubMedCrossRef

31.

Haria M, Benfield P (1995) Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 50:873–896PubMed

32.

Leroy V, Baud M, de Traversay C et al (1998) Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol 28:375–381PubMedCrossRef

33.

Antonelli G, Simeoni E, Bagnato F et al (1999) Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci 168:131–136PubMedCrossRef

34.

Antonelli G, Bagnato F, Pozzilli C et al (1998) Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. J Interferon Cytokine Res 18:345–350PubMedCrossRef

35.

Ross C, Engler CB, Sander B et al (2002) IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a. J Interferon Cytokine Res 22:421–426PubMedCrossRef

Title: Interferon-α2a and Vogt–Koyanagi–Harada disease: a double-edged sword?
Authors: Valerie Touitou
Damien Sene
Christine Fardeau
Thi-Huong-Du Boutin
Pierre Duhaut
Jean-Charles Piette
Phuc LeHoang
Patrice Cacoub
Bahram Bodaghi
Publication date: 01-06-2007
Publisher: Kluwer Academic Publishers
Published in: International Ophthalmology / Issue 2-3/2007
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-007-9040-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Interferon-α2a and Vogt–Koyanagi–Harada disease: a double-edged sword?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2007

Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt–Koyanagi–Harada disease

Vogt–Koyanagi–Harada disease diagnostic criteria

Peripheral iris depigmentation and ocular hypotony: result of the natural course of non-treated Vogt–Koyanagi–Harada (VKH) disease

Spectrum of Vogt-Koyanagi-Harada disease in Singapore

Retinal fluorescein and indocyanine green angiography and optical coherence tomography in successive stages of Vogt-Koyanagi-Harada disease

The spectrum of Vogt-Koyanagi-Harada disease in Turkey